In vitro assays for new drug screening: comparison of a thymidine incorporation assay with the human tumor colony-forming assay.
In vitro assays for new drug screening: comparison of a thymidine incorporation assay with the human tumor colony-forming assay.
复制标题
新药筛选的体外测定：胸苷掺入测定与人肿瘤集落形成测定的比较。
DOI：
10.1002/stem.5530050507
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
Kern,DH
中科院分区：
文献类型：
--
作者：
Hildebrand-Zanki,SU;Kern,DH
由于人类肿瘤集落形成试验(HTCFA)的技术限制，我们确定了使用胸腺嘧啶核苷掺入试验(TIA)进行新药筛选的可行性。TIA和HTCFA的一致性(r=0.840)与编码的20个化合物一致。在两种检测中，未证明临床疗效的有毒物质都是有效的，而无毒物质是无效的。TIA的生长率(75%)高于HTCFA(45%)，TIA可在6天内完成，而HTCFA为14-21天。我们的结论是，TIA是体内肿瘤模型筛选新抗癌药物的有用辅助手段。
Because of technical limitations with the human tumor colony‐forming assay (HTCFA), we determined the feasibility of using a thymidine incorporation assay (TIA) for new drug screening. Concordance between the TIA and the HTCFA was obtained (r = 0.840) with twenty coded compounds. Toxic agents without proven clinical efficacy were active in both assays, while non‐toxic substances were inactive. Growth rates were higher with the TIA (75%) than with the HTCFA (45%), and the TIA could be completed in 6 days compared to 14–21 days with the HTCFA. We concluded that the TIA is a useful adjunct to in vivo tumor models for screening new anticancer agents.